Gemcitabine in combination with vinorelbine and dexamethasone for relapsed non-Hodgkin's lymphoma

Abstract

Objective To explore the clinical value of Gemcitabine in combination with vinorelbine and dexamethasone in the treatment of relapsed non-Hodgkin's lymphoma.Methods 18 patients with nonHodgkin's lymphoma were treated with gemcitabine hydrochloride,Vinorelbine,and dexamethasone.The efficacy,adverse reactions,and tumor progression were observed.Results The overall effective rate was 55.56％.The complete remission rate was 22.22％.There was no statistical difference(x2 =0.969,P =0.809)in classification between B and T cells.Bone marrow suppression was the common toxicity.5 patients had gastrointestinal reactions.1 patient occurred mild liver dysfunction.After two years follow-up,it showed that 10 patients had no tumor progression,the other 8 patients (44.4％) progressed in tumor in average 4.9 months.Conclusions Gemcitabine in combination with vinorelbine and dexamethasone for non-Hodgkin's lymphoma has a good recent efficacy,few adverse reactions,and a low recurrence rate. Key words: Gemcitabine; Vinorelbine; Dexamethasone; Relapsed non-Hodgkin's lymphoma; Efficacy; Tumor progression time